What is William Blair's Forecast for VTGN Q1 Earnings?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - William Blair issued their Q1 2027 earnings per share estimates for VistaGen Therapeutics in a research note issued on Wednesday, June 18th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.37) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for VistaGen Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for VistaGen Therapeutics' Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.48) EPS and Q4 2027 earnings at ($0.41) EPS.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its earnings results on Tuesday, June 17th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.10. The business had revenue of ($0.01) million during the quarter, compared to analysts' expectations of $0.18 million. VistaGen Therapeutics had a negative return on equity of 55.31% and a negative net margin of 6,777.08%. During the same quarter last year, the firm posted ($0.25) earnings per share.

VistaGen Therapeutics Stock Down 13.4%

VTGN stock opened at $2.06 on Thursday. The firm has a 50 day moving average of $2.31 and a two-hundred day moving average of $2.58. VistaGen Therapeutics has a 12 month low of $1.90 and a 12 month high of $4.21. The company has a market capitalization of $59.45 million, a price-to-earnings ratio of -1.24 and a beta of 0.70.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new stake in VistaGen Therapeutics during the 1st quarter worth about $25,000. Two Sigma Advisers LP bought a new position in VistaGen Therapeutics in the fourth quarter valued at about $35,000. Man Group plc acquired a new stake in VistaGen Therapeutics in the fourth quarter worth about $54,000. Bank of America Corp DE raised its holdings in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock worth $62,000 after purchasing an additional 19,331 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in VistaGen Therapeutics during the 4th quarter worth about $66,000. Institutional investors own 78.39% of the company's stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.